Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling [Yahoo! Finance]
Axsome Therapeutics (AXSM) was upgraded by Truist Financial Corporation to "strong-buy".
Axsome Therapeutics (AXSM) had its price target raised by Guggenheim from $220.00 to $245.00. They now have a "buy" rating on the stock.
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain [Yahoo! Finance]